



# AMD Center of Excellence<sup>®</sup>

## Medical Model – Special Testing Day

 **Patient age 50 or older presents for Comprehensive Eye Exam**



 **Evaluate for AMD Symptoms or Signs during Patient History (Night Vision Complaint or Drusen)**


**YES** 

**NO**

**Comprehensive Eye Exam**  
Schedule patient back for special testing day to complete AdaptDx<sup>®</sup>



**Standard pre-exam testing and comprehensive eye exam**

 **Special Testing Day**  
Conduct AdaptDx test to determine Rod Intercept™ (RI™)  
Review test results with patient



**RI < 6.5**  
No additional treatment required for AMD  
Repeat imaging and AdaptDx Rapid Test annually

**RI ≥ 6.5**  
Schedule medical office visit to evaluate for advanced AMD  
Utilize imaging technology and AdaptDx Extended Test

### DECISION POINTS

What percent of your patients are over 50? \_\_\_\_\_%

Will you:

Use AMD Risk & Assessment Form from MacuLogix<sup>®</sup>

or

Ask screening questions, such as:

- Have you experienced any trouble seeing at night?
- Do you have trouble navigating or driving at night?
- Has it become more difficult to see in dim light?

Who is responsible for handing out form or asking screening questions?  
\_\_\_\_\_

Do you reserve certain days for special testing?

Which ones? \_\_\_\_\_ How many? \_\_\_\_\_

Will you utilize the Rapid Test or Extended Test?  
\_\_\_\_\_

Where will the testing be done? \_\_\_\_\_

Who will administer the test? \_\_\_\_\_

What other tests will be scheduled with AdaptDx?  
\_\_\_\_\_

How many AdaptDx tests can be scheduled in one day?

How will the results be shared with the patient?

If RI ≥ 6.5 when will you reschedule patient for Extended Test? \_\_\_\_\_

Will you perform imaging on patient? \_\_\_\_\_

Will you prescribe nutraceuticals? \_\_\_\_\_

Will you recommend protective lenses? \_\_\_\_\_

# AMD Staging, Treatment and Management Guidelines

	Subclinical AMD	Early AMD	Intermediate AMD	Advanced AMD
<b>Functional Testing (Average Rod Intercept<sup>1</sup>)</b>	<b>RI <math>\geq</math> 6.5</b> The diagnostic specificity and sensitivity of the 6.5 minute cut-point for the presence of AMD is greater than 90%	<b>12.9</b> (+/- 6.1)	<b>16.6</b> (+/- 5.2)	<b>19.0</b> (+/- 4.5)
<p>Dark adaptation speed is correlated with disease severity. The AdaptDx<sup>®</sup> Extended Test is a useful aid for staging AMD severity based on these average RI times.</p>				
<b>Structural Imaging</b>	<ul style="list-style-type: none"> <li>No drusen or small drusen <math>\leq</math> 63 <math>\mu</math>m</li> <li>No pigmentary abnormalities</li> </ul>	<ul style="list-style-type: none"> <li>Medium drusen &gt; 63 <math>\mu</math>m and <math>\leq</math> 125 <math>\mu</math>m</li> <li>No pigmentary abnormalities</li> </ul>	<ul style="list-style-type: none"> <li>1 large druse &gt; 125 <math>\mu</math>m and/or</li> <li>Pigmentary abnormalities</li> </ul>	<ul style="list-style-type: none"> <li>Geographic atrophy (GA) or</li> <li>Choroidal neovascularization (CNV)</li> </ul>
<b>Treatment Guidelines<sup>2</sup></b>	<ul style="list-style-type: none"> <li>Prescribe smoking cessation program</li> <li>Prescribe nutritional supplementation</li> <li>Discuss lifestyle modifications with respect to diet and exercise</li> <li>Discuss systemic disease management</li> <li>Prescribe blue light protection</li> <li>Prescribe UVA and UVB protection</li> </ul>	<ul style="list-style-type: none"> <li>Monitor smoking cessation compliance</li> <li>Monitor nutritional supplementation</li> <li>Review diet and exercise regimen</li> <li>Partner with primary care provider on systemic disease management</li> <li>Check blue light protection</li> <li>Reinforce UVA and UVB protection</li> </ul>	<ul style="list-style-type: none"> <li>Monitor smoking cessation compliance</li> <li>Review vitamin and supplement recommendations</li> <li>Discuss diet and exercise regimen</li> <li>Manage systemic diseases with primary care provider</li> <li>Re-evaluate optical protection</li> </ul>	<ul style="list-style-type: none"> <li>Low vision rehabilitation for GA</li> <li>Anti-VEGF injections for CNV</li> </ul>
<b>Frequency of Exams</b>	<b>Every 6-12 months</b> to monitor for rapid progression with clinical exam, imaging and dark adaptation testing	<b>Every 6 months</b> to monitor for rapid progression with clinical exam, imaging and dark adaptation testing	<b>Every 3-6 months</b> to monitor for CNV with clinical exam, imaging and dark adaptation testing	Refer to Retina Specialist at first sign of CNV or GA

1. Jackson, G. R., Scott, I. U., Kim, I. K., Quillen, D. A., Iannaccone, A., & Edwards, J. G. (2014). Diagnostic Sensitivity and Specificity of Dark Adaptometry for detection of Age-Related Macular Degeneration. Investigative Ophthalmology & Visual Science, 55, 1427-1431.  
 2. Practical Guidelines for the Treatment of AMD, published as a supplement to Review of Optometry in October, 2017